Reduced fracture risk with early corticosteroid withdrawal after kidney transplant

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 649-659

  Nikkel, L E ^a   Mohan, S ^b   Zhang, A ^b   McMahon, D J ^b   Boutroy, S ^b   Dube, G ^b   Tanriover, B ^b   Cohen, D ^b   Ratner, L ^b   Hollenbeak, C S ^a   Leonard, M B ^c   Shane, E ^b   Nickolas, T L ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Howard Hughes Medical Institute   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Corticosteroid; fracture; immunosuppression; kidney; renal; transplantation; USRDS

Indexed keywords

CORTICOSTEROID;

ADULT; ANKLE FRACTURE; ARTICLE; BONE MASS; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FEMUR FRACTURE; FOLLOW UP; FRACTURE; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RISK REDUCTION; SPINE FRACTURE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; GRAFT REJECTION; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84857640853     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03872.x     Document Type: Article

References (64)

1. Abbott KC, Oglesby RJ, Hypolite IO, et al,. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol 2001; 11: 450-457. (Pubitemid 32824108)
2. Vautour LM, Melton LJ, 3rd, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT,. Long-term fracture risk following renal transplantation: A population-based study. Osteoporos Int 2004; 15: 160-167. (Pubitemid 38252430)
3. Ball AM, Gillen DL, Sherrard D, et al,. Risk of hip fracture among dialysis and renal transplant recipients. JAMA: J Am Med Assoc 2002; 288: 3014-3018. (Pubitemid 35471163)
4. Palmer SC, McGregor DO, Strippoli GF,. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007; 3: CD005015.
5. Palmer SC, Strippoli GF, McGregor DO,. Interventions for preventing bone disease in kidney transplant recipients: A systematic review of randomized controlled trials. AmJ Kidney Dis 2005; 45: 638-649. (Pubitemid 40460752)
6. OPTN/SRTR Annual report: One year adjusted annual patient survival by organ and year of transplant, 1998 to 2007. Available from:. Accessed May 31, 2011.
7. Collins AJ, Foley RN, Gilbertson DT, Chen SC,. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 2009; 4 (Suppl 1): S5-S11.
8. Mikuls TR, Julian BA, Bartolucci A, Saag KG,. Bone mineral density changes within six months of renal transplantation. Transplantation 2003; 75: 49-54. (Pubitemid 36139694)
9. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD,. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544-550.
10. Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger PH,. Changes in bone mass early after kidney transplantation. J Bone Mineral Res 1994; 9: 1-9.
11. Moreno A, Torregrosa JV, Pons F, Campistol JM, Martínez de Osaba MJ, Oppenheimer F,. Bone mineral density after renal transplantation: Long-term follow-up. Transplant Proc 1999; 31: 2322-2323. (Pubitemid 29433932)
12. Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ,. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation 1995 15; 59: 982-986.
13. Braga JW Jr., Neves RM, Pinheiro MM, et al,. Prevalence of low trauma fractures in long-term kidney transplant patients with preserved renal function. Braz J Med Biol Res 2006; 39: 137-147. (Pubitemid 43091538)
14. Luan FL, Steffick DE, Gadegbeku C, Norman SP, Wolfe R, Ojo AO,. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009; 9: 160-168.
15. Luan FL, Steffick DE, Ojo AO,. Steroid-free maintenance immunosuppression in kidney transplantation: Is it time to consider it as a standard therapy? Kidney Int 2009; 76: 825-830.
16. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P,. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
17. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC,. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with thymoglobulin in living-donor kidney transplantation. Clin Transplant 2010; 24: 73-83.
18. Dube GK EZ, Thompson AM, Hardy MA, Ratner LE, Cohen DJ,. Early withdrawal of steroids in high risk transplant recipients. J Am Soc Nephrol 2007; 18 (Suppl): 232A.
19. Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C,. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: A prospective study. Transplantation 1997; 63: 380-386. (Pubitemid 27086029)
20. Farmer CK, Hampson G, Abbs IC, et al,. Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant 2006; 6: 2929-2936.
21. van den Ham EC, Kooman JP, Christiaans ML, van Hooff JP,. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transpl Int 2003; 16: 82-87. (Pubitemid 36682203)
22. Ing SW, Sinnott LT, Donepudi S, Davies EA, Pelletier RP, Lane NE,. Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients. Clin Transplant 2010; 25: E113-E123.
23. Greer JW,. End stage renal disease and Medicare. Health Care Financ Rev 2003; 24: 1-5. (Pubitemid 37264938)
24. System USRD. USRDS 2009 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
25. Available from:. Accessed May 18, 2011.
26. Mackey DC, Lui LY, Cawthon PM, et al,. High-trauma fractures and low bone mineral density in older women and men. Jama. [Research Support, N.I.H., Extramural] 2007; 298: 2381-2388. (Pubitemid 350190779)
27. Alem AM, Sherrard DJ, Gillen DL, et al,. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399. (Pubitemid 30429887)
28. Stehman-Breen CO, Sherrard DJ, Alem AM, et al,. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 2200-2205.
29. Nickolas TL, McMahon DJ, Shane E,. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006; 17: 3223-3232. (Pubitemid 44707784)
30. Coco M, Rush H,. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
31. Mussolino ME, Looker AC, Madans JH, Langlois JA, Orwoll ES,. Risk factors for hip fracture in white men: The NHANES I epidemiologic follow-up study. J Bone Miner Res 1998; 13: 918-924. (Pubitemid 28265269)
32. Ensrud KE, Lipschutz RC, Cauley JA, et al,. Body size and hip fracture risk in older women: A Prospective study. Study of Osteoporotic Fractures Research Group. Am J Med 1997; 103: 274-280. (Pubitemid 27459253)
33. D'Agostino RB, Jr., Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281. (Pubitemid 28466823)
34. Adinoff AD, Hollister JR,. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265-268. (Pubitemid 13074917)
35. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C,. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000. (Pubitemid 30350061)
36. Lukert BP, Raisz LG,. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990; 112: 352-364. (Pubitemid 20083611)
37. Dempster DW,. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989; 4: 137-141. (Pubitemid 19121785)
38. Dempster DW, Arlot MA, Meunier PJ,. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calc Tiss Int 1983; 35: 410-417. (Pubitemid 13028605)
39. Chavassieux P, Pastoureau P, Chapuy MC, Delmas PD, Meunier PJ,. Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: A biochemical and histomorphometric study. Osteoporos Int 1993; 3: 97-102. (Pubitemid 23088903)
40. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD,. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627-1633. (Pubitemid 28492231)
41. Lane NE, Lukert B,. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998; 27: 465-483. (Pubitemid 28285876)
42. Lukert BP, Raisz LG,. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994; 20: 629-650. (Pubitemid 24271581)
43. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al,. Increased risk of fracture in patients receiving solid organ transplants. J Bone Mineral Res 1999; 14: 456-463. (Pubitemid 29106723)
44. Shane E, Addesso V, Namerow PB, et al,. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004; 350: 767-776. (Pubitemid 38209646)
45. Leidig-Bruckner G, Hosch S, Dodidou P, et al,. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study. Lancet 2001; 357: 342-347. (Pubitemid 32128540)
46. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ,. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 1994; 58: 912-915. (Pubitemid 24333282)
47. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE,. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829-839. (Pubitemid 29214678)
48. O'Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL,. Risk factors for fractures in kidney transplantation. Transplantation 2002; 74: 362-366.
49. Coco M, Glicklich D, Faugere MC, et al,. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676. (Pubitemid 37169355)
50. Grotz W, Nagel C, Poeschel D, et al,. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12: 1530-1537. (Pubitemid 32666337)
51. Walsh SB, Altmann P, Pattison J, et al,. Effect of pamidronate on bone loss after kidney transplantation: A randomized trial. Am J Kidney Dis 2009; 53: 856-865.
52. De Sevaux RG, Hoitsma AJ, Corstens FH, Wetzels JF,. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: A randomized study. J Am Soc Nephrol 2002; 13: 1608-1614. (Pubitemid 34579249)
53. Torres A, Garcia S, Gomez A, et al,. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004; 65: 705-712. (Pubitemid 38130669)
54. Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM,. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 2004; 78: 1233-1236. (Pubitemid 39426447)
55. Miller PD,. The kidney and bisphosphonates. Bone 2011; 49: 77-81.
56. Neer RM,. Skeletal safety of tiludronate. Bone 1995; 17 (Suppl 5): 501S-503S.
57. Avramidis A, Polyzos SA, Moralidis E, et al,. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. J Bone Min Metabol 2008; 26: 635-641.
58. Schilcher J, Michaelsson K, Aspenberg P,. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364: 1728-1737.
59. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E,. Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008; 23: 1435-1441.
60. Cummings SR, Black DM, Thompson DE, et al,. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. Jama 1998; 280: 2077-2082. (Pubitemid 29014065)
61. Nikkel LE, Hollenbeak CS, Fox EJ, Uemura T, Ghahramani N,. Risk of fractures after renal transplantation in the United States. Transplantation 2009; 87: 1846-1851.
62. Elmstedt E,. Spontaneous fractures in the renal graft recipient: A discriminant analysis of 144 cases. Clin Orthop Relat Res 1982; 162: 195-201. (Pubitemid 12180756)
63. Rike AH, Mogilishetty G, Alloway RR, et al,. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: Comparison of early steroid withdrawal and chronic steroids. Clin Transplant 2008; 22: 229-235. (Pubitemid 351420018)
64. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ,. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185. (Pubitemid 36323115)